The insulin-sensitizing properties of thiazolidinediones (TZDs), a family of PPARγ agonist compounds used to treat type 2 diabetes, have been traditionally attributed to their ability to enhance adipogenesis, via activation of PPARγ [16]. This evidence concerns the gene INS and type 2 diabetes mellitus.